Press Releases
Information updates and press releases issued by Deep Genomics

Deep Genomics Appoints Jeffrey M. Brown, Ph.D., Vice President of Preclinical Research

May 3, 2021


TORONTO – May 3, 2021. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, Preclinical Research. Jeffrey will be responsible for advancing programs into IND-enabling studies, overseeing the discipline of experimental biology, and working with ...

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

November 17, 2020

 Deep Genomics

SAN RAFAEL and TORONTO, Nov. 17, 2020 — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in ...

Amanda Kay Appointed Chief Business Officer of Deep Genomics, Tasked with Overseeing Expansion of Partnership Strategy

November 5, 2020

Company also announces appointment of Tom Hughes, Boston-based biotech builder and CEO of  Navitor Pharmaceuticals, to board of directors.
Company now advancing multiple programs in neurodevelopmental, neurodegenerative and  metabolic disorders.

TORONTO – November 5, 2020. Deep Genomics, the leading artificial intelligence (AI) therapeutics  company, announced today ...

Deep Genomics Appoints Veteran Ferdinand Massari as Chief Medical Officer

September 29, 2020


TORONTO September 29, 2020. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that Ferdinand Massari, M.D., has been appointed Chief Medical Officer. Dr. Massari is based in Boston and will oversee clinical development and contribute to expanding the company’s AI ...

DEEP GENOMICS RAISES $40 MILLION IN SERIES B FINANCING

January 7, 2020


  •   Led by Future Ventures, includes top healthcare and technology funds Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures

  •   Proceeds will support creating new technology for artificial intelligence-accelerated therapeutic development and advancing Wilson disease program into the clinic 

TORONTO – January 7, 2020. Deep Genomics, the ...

DEEP GENOMICS NOMINATES INDUSTRY'S FIRST AI - DISCOVERED THERAPEUTIC CANDIDATE

September 25, 2019

Artificial Intelligence enables target and drug candidate to be identified in less than 18 months. Initial target of Wilson disease represents significant clinical need, new era of drug discovery.

Toronto, Ontario ​– September 25, 2019. Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder.

“This is ...

DEEP GENOMICS PLANS FOR CLINICAL INNOVATION, APPOINTS PETER BARTON HUTT AS STRATEGIC ADVISOR

June 25, 2019

 Deep Genomics is proud to announce that Peter Barton Hutt, Senior Counsel at Covington & Burling and former Chief Counsel of the U.S. Food and Drug Administration, has joined the company as a Strategic Advisor. 

Toronto, Ontario – June 26, 2019 at 9:00 AM EDT. Deep Genomics, the leading AI therapeutics company, announced today that Peter Barton Hutt, Senior Counsel at Covington & Burling and former Chief Counsel of the U.S. Food and Drug Administration, has joined the company ...